Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Renal Cell 35Carcinoma, Hepatocellular 17Neoplasm Metastasis 15Prostatic Neoplasms 13Neoplasms 9Neuroendocrine Tumors 7Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 6Brain Neoplasms 6Sarcoma, Ewing 5Sarcoma 5Osteosarcoma 5Kidney Neoplasms 5Colorectal Neoplasms 5Carcinoma, Transitional Cell 5Recurrence 4Pancreatic Neoplasms 4Multiple Myeloma 4Clear-cell metastatic renal cell carcinoma 4Urinary Bladder Neoplasms 3Lung Neoplasms 3Carcinoid Tumor 3Adenocarcinoma 3Uterine Cervical Neoplasms 2Thyroid Neoplasms 2Thyroid Diseases 2Pheochromocytoma 2Paraganglioma 2Neurofibroma, Plexiform 2Melanoma 2

Interventions

pembrolizumab 1lenvatinib 1camrelizumab 1cabozantinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Advanced Hepatocellular Carcinoma × cabozantinib × Clear all
NCT04442581 2023-04-05

Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer

University of Washington

Phase 2 Terminated
2 enrolled 12 charts
Gastrointestinal

Advanced Hepatocellular Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡